MRI contrast-enhancing preparations

DRUG2 trials

Sponsors

Sanofi

Conditions

Multiple Sclerosis

Phase 2

Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

Active, not recruitingNCT04879628

SanofiMultiple Sclerosis

Start: 2021-06-07End: 2027-08-23Updated: 2025-09-30

Phase 3

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

RecruitingNCT07325292

SanofiMultiple Sclerosis

Start: 2026-01-14End: 2028-11-30Target: 160Updated: 2026-03-23

Related Papers

Safety and Efficacy of Frexalimab in Relapsing Multiple Sclerosis: 48-week Results from the Phase 2 Open-label Extension (S31.007)

Neurology2024-04-09

Inhibition of CD40L with Frexalimab in Multiple Sclerosis

New England Journal of Medicine2024-02-1464 citations